Adenosine and the nervous system: Clinical implications

Clinical Neuropharmacology

Volumn 19, Issue 6, 1996, Pages 459-474

  Guieu, R ^a   Couraud, F ^b   Pouget, J ^c   Sampieri, F ^a   Bechis, G ^a   Rochat, H ^a  

^a CNRS   (France)

^b INSERM   (France)

^c TIMONE HOSPITAL   (France)

Author keywords

Adenosine; Dopamine; Epilepsy; Ischemia; Pain

Indexed keywords

ADENOSINE DERIVATIVE; DOPAMINE;

ALCOHOLISM; ALERTNESS; BRAIN ISCHEMIA; CATALEPSY; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; DOPAMINERGIC SYSTEM; DRUG METABOLISM; DYSKINESIA; EPILEPSY; HUMAN; NEUROPATHY; NOCICEPTION; PAIN; PRIORITY JOURNAL; REVIEW;

EID: 0029802956     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619060-00001     Document Type: Review

References (208)

1. Morff RJ, Granger HJ. Contribution of adenosine to arteriolar autoregulation in striated muscle. Am J Physiol 1983;244:567-76.
2. Runold M, Cherniak NS, Prabhakar NR. Effect of adenosine on isolated and superfused cat carotid body activity. Neurosci Lett 1990;113:111-4.
3. Sahlin K, Palmskog G, Hultman E. Adenine nucleotides and IMP contents in the quadriceps muscle in man after exercise. Pflugers Arch 1978;374:193-8.
4. Sollevi A. Cardiovascular effects of adenosine in man; possible clinical implications. Prog Neurobiol 1986;27:319-49.
5. Baer HP, Drummond GI. Physiological and regulatory functions of adenosine and adenine nucleotides. New York: Raven Press, 1979.
6. Ramkumar V, Stiles GL, Beaven MA, Ali H. The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem 1993;268:16887-90.
7. Schwabe U. General aspects of binding of ligands to adenosine receptors. In: Berne RM, Rail TW, Rubio TR, eds. Regulatory function of adenosine. Boston: Martinus Nijhoff, 1983:77-96.
8. Burnstock G. A basis for distinguishing two types of purinergic receptor. In: Straub RW, Bolis L, eds. Cell membrane receptors for drugs and hormones. New York: Raven Press, 1978:107-18.
9. Burnstock G. Purinergic nerves and receptors. Prog Biochem Pharmacol 1980;16:141-54.
10. Clarke B, Coupe M. Adenosine as a therapeutic agent. Int J Cardiol 1989;23:1-10.
11. Pelleg A, Porter S. The pharmacology of adenosine. Phannacotherapy 1990;10:157-74.
12. Phillis JW, Kostopoulos GK, Limacher JJ. A potent depressant action of adenine derivatives on cerebral cortical neurons. Eur J Pharmucol 1975;30:125-9.
13. Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB. Neuroprotective role of adenosine in cerebral ischemia. Trends Pharmacol Sci 1992;12:439-45.
14. Snyder SH. Adenosine as a neuromodulator. Annu Rev Neurosci 1985;8:103-24.
15. Spignoli G, Pedata F, Pepeu G. A1 and A2 adenosine receptors modulate acetylcholine release from brain slices. Eur J Pharmacol 1984;97:341-2.
16. Stiles GL. Adenosine receptors and beyond: molecular mechanisms of physiologic regulation. Clin Res 1990;38:10-8.
17. Lowenstein JM, Yu MK, Naito Y. Regulation of adenosine metabolism by 5′-nucleotidases In: Berne RM, Rail TW, Rubio R, eds. Regulatory function of adenosine. The Hague: Martinus Nijhoff, 1987:117-31.
18. Arch JRS, Newsholme EA. The control of the metabolism and the hormonal role of adenosine. Essays Biochem 1978;14:82-123.
19. Coade SB, Pearson JD. Metabolism of adenine nucleotides in human blood. Circ Res 1989;65:531-7.
20. Smolenski RT, Kochan Z, Mc Douall R, Page C, Seymour AML, Yacoub MH. Endothelial nucleotide catabolism and adenosine production. Cardiovasc Res 1994;28:100-4.
21. Klabunde RE, Althouse DG. Adenosine metabolism in dog whole blood: effects of dipyridamole. Life Sci 1981;23:2631-41.
22. Moser GH, Schrader J, Deussen A. Turnover of adenosine in plasma of human and dog blood. Am J Physiol 1989;256:C799-806.
23. Ontyd J, Schrader J. Measurement of adenosine, inosine and hypoxanthine in human plasma. J Chromatogr 1984;307:404-9.
24. Plagemann PG, Wohlhueter RM, Kraupp M. Adenosine uptake, transport and metabolism in human erythrocytes. J Cell Physiol 1985;125:330-6.
25. Guieu R, Sampieri F, Bechis G, Rochat H. Use of HPLC to measure circulating adenosine levels in migrainous patients. Clin Chim Acta 1994;227:185-94.
26. Guieu R, Paganelli F, Sampieri F, Bechis G, Levy S, Rochat H. The use of HPLC to evaluate the variations of blood coronary adenosine levels during percutaneous transluminal angioplasty. Clin Chim Acta 1994;230:63-8.
27. Klabunde RE. Dipyridamole inhibition of adenosine metabolism in human blood. Eur J Pharmacol 1983;93:21-6.
28. Kocesis JD, Eng DL, Bhisitkul RB. Adenosine selectively blocks parallel fibre-mediated synaptic potentials in rat cerebellar cortex. Proc Natl Acad Sci USA 1984;81:6531-4.
29. Namm DH, Leader JP. A sensitive analytical method for the detection and quantitation of adenosine in biological samples. Anal Biochem 1974;58:511-27.
30. 3H-1,3-dipropyl-8-cyclopentylxanthine in frog brain membranes. Br J Pharmacol 1993;109:518-23.
31. Shryock JC, Boykin MT, Hill JA, Belardinelli L. A new method of sampling blood for measurement of plasma adenosine. Am J Physiol 1990;258:H1232-9.
32. Fredholm BB, Hedqvist P. Modulation of neurotransmission by purine nucleotides and nucleosides. Biochem Pharmacol 1980;29:1635-43.
33. Hollins C, Stone T. Adenosine inhibition of GABA release from slices of rat cerebral cortex. Br J Pharmacol 1980;69:107-12.
34. Johnston ME, Geiger JD. Sodium-dependent uptake of nucleosides by dissociated brain cells from the rat. J Neurochem 1989;1:75-81.
35. Jonzon B, Fredholm BB. Release of purines, noradrenaline and GABA from rat hippocampal slices by field stimulation. J Neurochem 1985;44:217-24.
36. Meghji P, Tuttle JB, Rubio R. Adenosine formation and release by embryonic chick neurons and glia in cell culture. J Neurochem 1989;6:1852-60.
37. + and veratridine. J Neurochem 1985;45:791-7.
38. Caciagli F, Ciccarelli P, Dilorio P, Ballerini P, Tacconelli L, Cultured glial cells release purines under field electrical stimulation: the possible ionic mechanism. Pharmacol Res Commun 1988;20:935-47.
39. Lehmann A. Evidence for a direct action of N-methylaspartate on nonneuronal cells. Brain Res 1987;411: 95-101.
40. Dodd J, Solter D, Jessel TM. Monoclonal antibodies against carbohydrate differentiation antigens identify subsets of primary sensory neurons. Nature 1984;31:469-72.
41. Holton P. The liberation of ATP on antidromic stimulation of sensory nerves. J Physiol 1959;145:494-504.
42. Holton FA, Holton P. The capillary dilator substances in dry powders of spinal roots: a possible role of ATP in chemical transmission from nerve endings. J Physiol 1954;126:124-40.
43. Jarvis SM. Kinetic and molecular properties of nucleoside transporters in animal cells; In: Gerlach E, Becker BF, eds. Topics and perspectives in adenosine research. Berlin: Springer-Verlag, 1987:102-16.
44. Plagemann PGW, Wohlhueter RM, Erbe J. Nucleoside transport in human erythrocytes. A simple carrier with directional symmetry and differential mobility of loaded and empty carrier. J Biol Chem 1982;257: 12069-74.
45. Bender AS, Hertz L. Similarities of adenosine uptake systems in astrocytes and neurons in primary culture. Neurochem Res 1986;11:1507-24.
46. 3H) adenosine uptake into cerebral cortical synaptosomes. J Neurochem 1980;35:629-40.
47. Angielski S, Le Hir M, Dubach UC. Transport of adenosine by renal border membranes. Pflugers Arch 1983;397:75-7.
48. Ungemach FR, Hegner D. Uptake of thymidine into isolated rat hepatocytes: evidence for two transport systems. Physiol Chem 1978;359:845-56.
49. Paterson ARP, Jacobs ES, Neg CY, Odegard RD, Adjei AA. Nucleoside transport inhibition in vitro and in vivo. In: Gerlach E, Becker BF, eds. Topics and perspectives in adenosine research. New York: Springer-Verlag, 1987:89-101.
50. Schwenk M, Hegazy E, Lopez del Pino V. Uridine uptake by isolated epithelial cells of guinea pig. Biochim Biophys Acta 1984;805:370-4.
51. Jarvis SM, McBride D, Young JD. Erythrocyte nucleoside transport: asymmetrical binding of nitrobenzylthioinosine to nucleoside permeation sites. J Physiol 1982;324:31-46.
52. Kolassa N, Pfleger K, Rummel W. Specificity of adenosine uptake into the heart and inhibition by dipyridamole. Eur J Pharmacol 1970;9:265-8.
53. Kolassa N, Plank B, Turnheim K. pH and temperature dependence of adenosine uptake in human erythrocytes. Eur J Pharmacol 1978;52:345-51.
54. Strauss PR, Shichan JM, Kashket ER. Membrane transport by murine lymphocytes. The appearance of thymidine transport in cells from concanavalin A-stimulated mice. J Immunol 1977;118:1328-34.
55. Trimble ME, Coulson R. Adenosine transport in perfused rat kidney and renal cortical membrane vesicles. Am J Physiol 1984;15:F794-803.
56. Thampy KG, Barnes EM. Adenosine transport by cultured glial cells from chick embryo brain. Arch Biochem Biophys 1983;220:340-6.
57. Thampy KG, Barnes EM. Adenosine transport by primary cultures of neurons from chick embryo brain. J Neurochem 1983;40:340-6.
58. Wu PH, Phillis JW. Uptake by central nervous tissues as a mechanism for the regulation of extracellular adenosine concentration. Neurochem Int 1984;6:613-32.
59. Daly JW. Adenosine receptors. In: Cooper DMF, Seamon KB, eds. Advances in cyclic nucleotides and protein phosphorylation research. New York: Raven Press, 1985:29-45.
60. Fredholm BB, Abbrachio MP, Burnstock G, et al. Nomenclature and classification of purinoreceptors. Pharmacol Rev 1994;2:143-56.
61. Kennedy C, Ijzerman A. Adenosine and ATP; from receptor structure to clinical applications. Trends Pharmacol Sci 1994;15:311-2.
62. Salvatore CA, Jacobson MA, Taylor HE, Linden J, Johnson RG. Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci USA 1993;90:10365-9.
63. Turnheim K, Plank B, Kolassa N. Inhibition of adenosine-uptake in human erythrocytes by adenosine 5′-carboxamides, xylosyladenine, dipyridamole, hexobendine and p-nitrobenzylthioguanosine. Biochem Pharmacol 1978;27:2191-7.
64. Schubert P. Classification of purine receptors. In: Stefanovich V, Dolphin KAC, Schubert P, eds. Adenosine: receptors and modulation of cell function. Oxford; IRL, 1985:117-29.
65. Freissmuth M, Schutz W, Linder ME. Interactions of the bovine A1-adenosine receptor with recombinant G protein subunits. Selectivity for rGia-3. J Biol Chem 1991;266:17778-83.
66. Van Calker D, Muller M, Hamprecht B. Adenosine inhibits the accumulation of cyclic AMP in cultured brain cells. Nature 1978;276:839-41.
67. Van Calker D, Muller M, Hamprecht B. Adenosine regulates via two different types of receptors the accumulation of cyclic AMP in cultured brain cells. J Neurochem 1979;33:999-1005.
68. ++ currents and synaptic transmission in cultured rat hippocampal pyramidal neurones. J Physiol 1991;435:373-93.
69. Gerwins F, Fredholm BB. ATP and its metabolite adenosine act synergistically to mobilize intracellular calcium via the formation of inositol 1.4,5-triphosphate in a smooth muscle cell line. J Biol Chem 1992;267:6081-7.
70. Gerwins F, Fredholm BB. Adenosine A1 agonists stimulate protein kinase C in a smooth muscle line cell. J Biol Chem 1993;268:1801-6.
71. Stiles GL. Adenosine receptors: structure, function and regulation. Trends Pharmacol Sci 1986;7:486-90.
72. Delahunty TM, Cronin JM, Linden J. Regulation of GH3 cell function via adenosine A1 receptors. Inhibition of prolactin release, cyclic AMP production and inositol phosphate generation. Biochem J 1988;255:58-60.
73. Green RW, Haas HL. The electrophysiology of adenosine in the mammalian central nervous system. Prog Neurobiol 1991;36:329-41.
74. Williams M. Adenosine - a selective neuromodulator in the mammalian CNS. Trends Neurosci 1984;27: 164-8.
75. Akasu T, Shinnick-Gallagher R, Gallagher JP. Adenosine mediates a slow hyperpolarizing synaptic potential in autonomic neurones. Nature 1984;311:62-4.
76. Connolly GP, Stone TW. Ionic mechanism of action of adenosine on the rat superior cervical ganglion. J Autonom Pharmacol 1993;13:91-102.
77. Londos C, Cooper DMF, Wolff J. Subclasses of external adenosine receptors. Proc Natl Acad Sci USA 1980;77:2551-4.
78. Alexander SP, Reddington M. The cellular localization of adenosine receptors in rat neostriatum. Neuroscience 1989;3:645-51.
79. Premont J, Tassin J, Blanc G, Bockaert J. Effects of adenosine on broken cell preparations of central nervous system. In: Baer HP, Drummond GI, eds. Physiological and regulatory functions of adenosine and adenine nucleotides. New York: Raven Press, 1979:259-69.
80. Sebastiao AM, Ribeiro JA. 1,3,8 and 1,3,7-substituted xanthines: relative potency as adenosine receptor antagonists at the frog neuromuscular junction. Br J Pharmacol 1989;96:211-9.
81. Ginsborg BL, Hirst GDS. The effect of adenosine on the release of the transmitter from the phrenic nerve of the rat. J Physiol 1972;224:629-45.
82. Fastbom J, Fredholm BB. Regional differences in the effect of guanine nucleotides on agonist and antagonist binding to adenosine receptors in rat brain as revealed by autoradiography. Neuroscience 1990;34:759-69.
83. Wojcik WJ, Neff NH. Differential location of adenosine A1 and A2 receptors in striatum. Neurosci Lett 1983;41:55-60.
84. Goodman RR, Kuhar MJ, Hester L, Snyder SH. Adenosine receptors: autoradiographic evidence for their location on axon terminals of excitatory neurons. Science 1983;220:967-8.
85. 3H)adenosine in rat brain: effects of N-ethylmaleimide. Brain Res 1986;399:232-9.
86. 3H cyctohexyladenosine. J Neurosci 1982;2:1230-41.
87. Choca JJ, Proudfit HK, Green RD. Identification of A1 and A2 adenosine receptors in the rat spinal cord. J Pharmacol Exp Ther 1987;247:757-64.
88. Degenring FH, Curnish RR, Rubio R, Berne RM. Effect of dipyridamole on myocardial adenosine metabolism and coronary flow in hypoxia and reactive hyperemia in the isolated perfused guinea pig heart. J Mol Cell Cardiol 1976;8:877-88.
89. Sollevi A, Fredholm BB. Role of adenosine in adipose tissue circulation. Acta Physiol Scand 1981;112: 293-8.
90. Sollevi A, Link H, Fredholm BB. Dipyridamole treatment doubles the plasma adenosine level in patients with minor stroke. Thromb Haemost 1983;50:20-1.
91. ++ channel antagonists and ions. Am J Physiol 1985;248:H593-8.
92. Porter NM, Radulo-Vacki M, Green RD. Desensitization of adenosine and dopamine receptors in rat brain after treatment with adenosine analogs. J Pharmacol Exp Ther 1988;244:218-25.
93. Clanachan AS, Marshall RJ. Diazepam potentiates the coronary vasodilatator action of adenosine in anesthetized dogs. Br J Pharmacol 1980;70:66-67.
94. Koss FW, Beisenherz G, Maerkish R. Die eliminerung von adenosine aus dem blut unter dem einfluss von 2, 6-Bis-(diathanolamino)-4, 8-dipipenidino-pyrimido (5, 4-d) pyrimidin und papaverin. Arzneimittelforsch 1962;12:1130-1.
95. Gruber H, Hoffer ME, Mac Allister DR, et al. Increased adenosine concentration in blood, from ischemic myocardium by AICA riboside: effects on flow, granulocytes and injury. Circulation 1989;80:1400-11.
96. Mullane K, Acadesine, the prototype adenosine regulating agent for reducing myocardial ischemia. Cardiovasc Res 1993;27:43-7.
97. Daval JL, Nehlig A, Nicolas F. Physiological and pharmacological properties of adenosine; therapeutic implications. Life Sci 1991;49:1435-53.
98. Mosqueda-Garcia R. Adenosine as a therapeutic agent. Clin Invest Med 1992;15:445-55.
99. Williams M, Jarvis MF. Adenosine antagonists as potential therapeutic agents. Pharmacol Biochem Behav 1988;29:433-41.
100. Shi D, Nikodijevic O, Jacobson KA, Daly JW. Chronic caffeine alters the density of adenosine, adrenergic, cholinergic, GABA and serotonin receptors and calcium channels in mouse brain. Cell Mol Neurobiol 1993;13:247-9.
101. Salter MW, Henry JL. Evidence that adenosine mediates the depression of spinal dorsal horn neurones induced by vibration in the cat. Neuroscience 1987;22:631-50.
102. Ramkumar V, Pierson G, Stiles L, Immunological effects of adenosine agonists. In: Jucker E, ed. Progress in drug research, vol 32. Basel: Birkhauser, 1988:195-247.
103. Smith AD, Winkler H. Fundamental mechanisms of the release of catecholamines. In: Blaschko H, Muscholl E, eds. Catecholamines: handbook of experimental pharmacology, vol 33. Berlin: Springer-Verlag, 1972:538-617.
104. Von Borstel RW, Renshaw AA, Wurtman RJ. Adenosine strongly potentiates presser responses to nicotine in rats. Proc Natl Acad Sci USA 1984;81:5599-603.
105. Fredholm BB, Dunwiddie TV. How does adenosine inhibit transmitter release? Trends Pharmacol Sci 1988;9:130-4.
106. McIlwain I. Regulatory significance of the release and action of adenine derivates in cerebral systems. Biochem Soc Symp 1972;36:69-85.
107. Stone TW. Adenosine and the nervous system. New York: Academic Press, 1991.
108. Simon RP, Griffiths T, Evans MC, Swan JH, Meldrum BS. Calcium overload in selectively vulnerable neurons of the hippocampus during and after ischemia: an electron microscopy study. J Cereb Blood Flow Metab 1984;4:350-61.
109. Simon RP, Griffiths T, Meldrum BS. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 1984;226:850-2.
110. Dragunow M, Faulds RLM. Neuroprotective effects of adenosine. Trends Pharmacol Sci 1988;9:193.
111. Goldberg MP, Monyer H, Weiss JH, Choi DW. Adenosine reduces cortical neuronal injury induced by oxygen or glucose deprivation in vitro. Neurosci Lett 1988;89:323-7.
112. Evans MC, Swan JH, Meldrum BS. An adenosine analogue, 2-chloroadenosine, protects against long term development of ischemic cell loss in the rat hippocampus. Neurosci Lett 1987;83:287-92.
113. Phillis JW, Simpson RE, Walter GA. Brain adenosine and transmitter amino acid release from the ischemic rat cerebral cortex: effects of adenosine deaminase inhibitor deoxycoformycin. J Neurochem 1991;56: 644-50.
114. Schubert P, Kreutzberg GW. In: Krieglstein J, Oberpichler H, eds. Pharmacology of cerebral ischemia. Berlin Wiss Verlagsgesellshaft, 1990:417-26.
115. Hagberg H, Andersson P, Lacarewicz J, Jacobson L, Butcher S, Sandberg M. Extracellular adenosine, inosine, hypoxanthine and xanthine in relation to tissue nucleotides and purines in rat striatum during transient ischemia. J Neurochem 1987;49:227-31.
116. Ruhio R, Berne RM, Bookman EL, Curnish RR. Relationship between adenosine concentration and oxygen supply in rat brain. Am J Physiol 1975;228:1896-902.
117. Van Wylen DO, Park TS, Rubio R, Berne RM. Increases in cerebral interstitial fluid adenosine concentration during hypoxia, local potassium infusion, and ischemia. J Cereb Blood Flow Metab 1986;6:522-8.
118. Winn HR, Rubio R, Berne RM. Brain adenosine concentration during hypoxia in rats. Am J Physiol 1981;241:H235-42.
119. Winn HR, Welsh JE, Rubio R, Berne RM. Changes in brain adenosine during bicueulline-induced seizure in rats. Effects of hypoxia and altered systemic blood pressure. Circ Res 1980;47:568-77.
120. Yaksh TL. Direct evidence that spinal serotonin and noradrenaline terminals mediate the spinal antinociceptive effects of morphine in the periaqueductal gray. Brain Res 1979;160:180-5.
121. Matsumoto T, Kanaide H, Shogakiushi Y, Makamura M. Characteristics of the histamine-sensitive calcium store in vascular smooth muscle. Comparison with norepinephrine or caffeine-sensitive stores. J Biol Chem 1990;265:5610-4.
122. Lee CW, Jarvis SM. Nucleoside transport in rat and guinea pig synaptosomes. Pflugers Arch [Suppl] 1986;1:43-7.
123. Von Lubitz DKJE, Paul IA, Ji XD, Carter MF, Jacobson KA. Chronic adenosine A1 receptor agonist and antagonist: effect on receptor density and N-methyl-D-aspartate induced seizure in mice. Eur J Pharmacol 1994;253:95-9.
124. Hedqvist P, Fredholm BB. Effect of adenosine on adrenergic neurotransmission: prejunctional inhibition and postjunctional enhancement. Naunyn Schmiedebergs Arch Pharmacol 1976;293:217-23.
125. Corradetti R, Conte L, Moroni F, Passani MB, Pepeu G. Adenosine decreases aspartate and glutamate release from rat hippocampal slices. Eur J Pharmacol 1984;104:19-26.
126. Dolphin AC, Archer ER. An adenosine agonist inhibits and a cyclic AMP analogue enhances the release of glutamate but not GABA from slices of rat dentate gyrus. Neurosci Lett 1983;43:49-54.
127. Dolphin AC, Prestwich SA. Pertussis toxin reverses adenosine inhibition of neuronal glutamate release. Nature 1985;316:148-50.
128. Fastbom J, Fredholm BB. Inhibition of (3H) glutamate release from rat hippocampal slices by L-phenylisopropyl-adenosine. Acta Physiol Scand 1985;125:121-3.
129. Dunwiddie TV. The physiological role of adenosine in the central nervous system. Int Rev Biochem 1985;27:63-139.
130. Manzoni OJ, Manabe T, Nicoll RA. Release of adenosine by activation of NMDA receptors in the hippocampus. Science 1994;265:2098-101.
131. Miller LP, Hsu C. Therapeutic potential for adenosine receptor activation in ischemic brain injury. J Neurotrauma [Suppl] 1992;2:5563.
132. Mitchell JB, Lupica CR, Dunwiddie CV. Activity-dependent release of endogenous adenosine modulates synaptic responses in the rat hippocampus. J Neurosci 1993;13:3439-47.
133. Seibel PS, Theodore P, Kron IL, Tribble CG. Regional adenosine attenuates post-ischemic spinal cord injury. J Vasc Surg 1993;18:153-60.
134. Neavy JT, Rathbone MP, Cattabeni F, Abbrachio MP, Burnstock G. Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Trends Neurol Sci 1996;1:13-8.
135. Holmgren M, Hednar J, Mellstrand T, Nordberg G, Hedner T. Characterization of the anti-nociceptive effects of some adenosine analogues in the rat. Naunyn Schmiedebergs Arch Pharmacol 1986;334:290-3.
136. Sosnowski M, Stevens CW, Yaksh TL. Assessment of the role of A1/A2 adenosine receptors mediating the purine anti-nociception, motor and autonomic function in the rat spinal cord. J Pharmacol Exp Ther 1989;250:915-22.
137. Choca JJ, Green RD, Proudfit HK. Adenosine A1 and A2 receptors of the substantia gelatinosa are located predominantly on intrinsic neurons: an autoradiographic study. J Pharmacol Exp Ther 1988;247:757-64.
138. Choca JJ, Green RD, Proudfit HK. Autoradiographic evidence that spinothalamic tract neurons possess adenosine receptors. Soc Neurosci Abstr 1988;14:776.
139. Sawynok J, Sweeney MI, White TD. Adenosine release may mediate spinal analgesia by morphine. Trends Pharmacol Sci 1989;10:186-9.
140. Post C. Anti-nociceptive effects in mice after intrathecal injection of 5′-ethylcarboxamide adenosine. Neurosci Lett 1984;51:325-30.
141. Sawynok J, Reid A, Nance D. Spinal anti-nociception by adenosine analogs and morphine following intrathecal administration of the neurotoxins capsaicin, 6-hydroxydopamine and 5,7-dihydroxytryptamine. J Pharmacol Exp Ther 1991;258:370-80.
142. Aran S, Proudfit HK. Anti-nociception produced by interactions between intrathecally administered adenosine agonists and norepinephrine. Brain Res 1990;513:255-63.
143. Delander GE, Hopkins CJ. Spinal adenosine modulates descending anti-nociceptive pathways stimulated by morphine. J Pharmacol Exp Ther 1986;239:88-93.
144. Sawynok J, Sweeney MI, White TD. Classification of adenosine receptors mediating anti-nociception in the rat spinal cord. Br J Pharmacol 1986;88:923-30.
145. Wakade A, Wakade T. Inhibition of noradrenaline release by adenosine. J Physiol 1978;282:35-49.
146. Sawynok J, Reid A. Desipramine potentiates spinal antinociception by 5-hydroxytryptamine morphine and adenosine. Pain 1992;50:113-8.
147. Sawynok J, Reid A, Ishrucker R. Adenosine mediates calcium-induced anti-nociception and potentiation of noradrenergic antinociception in the spinal cord. Brain Res 1990;524:187-95.
148. Fredholm BB. Purinoreceptors in the nervous system. Pharmacol Toxicol 1995;76:228-39.
149. Sylven C, Beerman B, Jonzon B, Brant R. Angina pectoris-like pain provoked by intravenous adenosine in healthy volunteers. Br Med J 1986;293:227-30.
150. Conradson TBG, Dixon CMS, Clarke B, Barned PJ. Cardiovascular effects of infused adenosine in man; potentiation by dipyridamole. Acta Physiol Scand 1987;129:387-91.
151. Vasko MR, Ono H. Adenosine analogs do not inhibit the potassium stimulated release of substance P from rat spinal cord slices. Arch Pharmacol 1990;342:441-6.
152. Broad RM, McDonald RJ, Cook MA. Adenosine and 5HT inhibit substance P release from nerve endings in myenteric ganglia by distinct mechanisms. Am J Physiol 1993;264:G454-61.
153. Karlsten R, Gordh T, Post C. Local antinociceptive and hyperalgesic effects in the formalin test after peripheral administration of adenosine analogues in mice. Pain 1992;70:434-8.
154. Schrier DJ, Lesh ME, Wright CD, Gilbersten RB. The anti-inflammatory effects of adenosine receptor agonists on the carageenan-induced pleural inflammatory response in rats. J Immunol 1990;145:1874-9.
155. Lappin D, Whaley K. Adenosine A2 receptors on human monocytes modulate C2 production. Clin Exp Immunol 1984;57:454-60.
156. Mandler R, Birch RE, Polmar SH, Kammer GM, Rudolph SA. Abnormal adenosine-induced immunosuppression and cAMP metabolism in T lymphocytes of patients with systemic lupus erythematosus. Proc Natl Acad Sci USA 1982;79:7542-6.
157. Cronstein BN. A novel approach to the development of anti-inflammatory agents: adenosine release at inflamed sites. J Invest Med 1994;1:50-7.
158. Bonica JJ. Causalgia and other reflex sympathic dystrophies. In: Bonica JJ, Liebeskind JC, Albe-Fessard DG, eds. Proceedings of the Second World Congress on Pain, Montreal. New York: Raven Press, 1979:141-66. (Advances in pain research and therapy; vol 3).
159. Evoniuk GE, Von Borstel RW, Wurtman RJ. Adenosine affects sympathetic neurotransmission at multiple sites in vivo. J Pharmacol Exp Ther 1986;236:350-5.
160. Fredholm BB, Gustafsson LE, Hedqvist P, Sollevi A. Adenosine in the regulation of neurotransmitter release in the peripheral nervous system. In: Berne RM, Rail TW, Rubio R, eds. Regulatory functions of adenosine. Boston: Martinus Nijhoff, 1983:479-93.
161. Deray G, Granch RA, Herzer WA, Ohnishi A, Jackson EK. Adenosine inhibits β-adrenoreceptor but not D8-cAMP-induced renin release. Am J Physiol 1987;252:F46-52.
162. Guieu R, Tardy-Gervet MF, Blin O, Pouget J. Pain relief achieved by transcutaneous electrical stimulation and/or vibratory stimulation in a case of painful legs and moving toes syndrome. Pain 1990;42:43-8.
163. Guieu R, Tardy-Gervet MF, Roll JP. Analgesic effects of vibrations and transcutaneous electrical nerve stimulation applied separately or simultaneously. Can J Neurosci 1991 ;18:113-9.
164. Lundeberg T. Vibratory stimulation for the alleviation of chronic pain. Acta Physiol Scand 1983;523:1-51.
165. Guieu R, Sampieri F, Bechis G, Rochat H. Adenosine in painful legs and moving toes syndrome. Clin Neuropharmacol 1994;5:460-9.
166. Sollevi A, Belfrage M, Lundeberg T, Segardahl M, Hansson P. Systemic adenosine infusion: a new treatment modality to alleviate neuropathic pain. Pain 1995;61:155-8.
167. Leira J, Castillo F, Martinez F. Nucleotidos de la adenina en la migrana. Neurologia 1991;6:207-10.
168. Joseph R, Welch KMA, D'Andrea G. ATP hyposecretion from platelet dense bodies. Evidence for the purinergic hypothesis and a marker for migraine. Headache 1986;26:403-10.
169. Woods RP, Jacoboni M, Mazziotta JC. Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994;331:1689-92.
170. Anthony M. The biochemistry of migraine. In: Headache. 1986:85-105. (Handbook of clinical neurology: vol 4).
171. Durcan MJ, Morgan PF. NECA-induced hypomotility in mice: evidence for a predominantly central site of action. Biochem Behav 1989;32:487-90.
172. Schingitz G, Kufner-Muhl U, Ensinger H, Lehr E, Kuhn FJ. Selective A1 antagonists for treatment of cognitive deficits. Nucleotides Nucleosides 1991;10:1067-76.
173. Rainnie DG, Grunze HCR, Mc Carley RW, Greene RW. Adenosine inhibition of mesopontine cholinergic neurons: implications for EEG arousal. Science 1994;263:689-92.
174. Ault B, Wang CM. Adenosine inhibits epileptiform activity arising in hippocampal area CA3, Br J Pharmacol 1986;87:695-703.
175. Jacobson KA, Van Gallen PJM, Williams M. Adenosine receptors: pharmacology, structure-activity and therapeutic potential. J Med Chem 1992;35:407.
176. Murray TF, Sylvester D, Schultz CS, Szot P. Purinergic modulation of seizure threshold for pentylenetetrazol in the rat. Neuropharmacology 1985;24:761-5.
177. Schubert P, Lee KS. The anti-convulsive action of adenosine; a post-synaptic dendritic action by a possible endogenous anticonvulsant. Brain Res 1984;321:160-4.
178. Dragunow M. Adenosine and epileptic seizures. In: Phillis JW, ed. Adenosine and adenine nucleotides as regulators of cellular function. Boca Raton: CRC Press, 1991:367.
179. Dragunow M, Goddard GV, Laverty R. Is adenosine an endogenous anticonvulsant? Epilepsia 1985;26: 480-2.
180. Dunwiddie TV. Endogenously released adenosine regulates excitability in the in vitro hippocampus. Epilepsia 1980;21:541-8.
181. Zhang G, Franklin PH, Murray TF. Manipulation of endogenous adenosine in the rat pre-pyriform cortex modulates seizure susceptibility. J Pharmacol Exp Ther 1993;264:1415-82.
182. Gerber U, Greene RW, Haas HL, Stevens DR. Characterization of inhibition mediated by adenosine in the hippocampus of the rat in vitro. J Physiol 1989;417:567-78.
183. Haas HL, Greene RW. Endogenous adenosine inhibits hippocampal CA1 neurons: further evidence from extra- and intracellular recording. Naunyn Schmiedebergs Arch Pharmacol 1988;337:561-5.
184. Lee K, Schubert P, Heinemann U. The anticonvulsive action of adenosine: a post-synaptic, dendritic action by a possible endogenous anticonvulsant. Brain Res 1984;321:160-4.
185. Proctor WR, Dunwiddie TV. Adenosine inhibits calcium spikes in hippocampal pyramidal neurons in vitro. Neurosci Lett 1983;35:177-87.
186. Young D, Dragunow M. Status epilepticus may be caused by loss of adenosine anticonvulsant mechanisms. Neuroscience 1994;2:245-61.
187. Fredholm BB, Fastbom J, Lindgren E. Effects of N-methylmaleimide and forskolin on glutamate release from rat hippocampal slices. Evidence that prejunctional adenosine receptors are linked to N-proteins but not adenylate cyclase. Acta Physiol Scand 1986;127:381-6.
188. Abbracchio MP, Colombo F, Di Luca M, Zaratin P, Cattabeni F. Adenosine modulates the dopaminergic function in the nigro-striatal system by interacting with striatal dopamine dependent adenylate cyclase. Pharmacol Res Commun 1987;19:275-86.
189. Green RD, Proudfit UK, Yeung SM. Modulation of striatal dopaminergic function by local injection of 5′-N-ethylcarboxamidoadenosine. Science 1982;218:58-61.
190. Michaelis M, Michaelis E, Myers S. Adenosine modulation of synaptosomal dopamine release. Life Sci 1979;24:2083-92.
191. Casas M, Ferre S, Cobos A, Grau JM, Jane F. Relation between rotational behaviour induced by apomorphine and caffeine in rats with unilateral lesion of the nigrostriatal pathway. Neuropharmacology 1989;28:407-9.
192. Fredholm BB, Fuxe K, Agnati LF. Effects of some phosphodiesterase inhibitors on central dopamine mechanisms. Eur J Pharmacol 1976;38:31-8.
193. Jiang H, Jackson-lewis V, Muthane U, et al. Adenosine receptor antagonists potentiate dopamine receptor agonist rotational behavior in 6-hydroxydopamine-lesioned rats. Brain Res 1993;613:347-51.
194. Ferre Sm Herrera-Marschitz M, Grabowska-Anden M, Ungerstedt U, Casas M, Anden NE. Post-synaptic dopamine/adenosine interaction. Adenosine analogs inhibit dopamine D2 mediated behaviour in short-term reserpinised mice. Eur J Pharmacol 1991;192:25-30.
195. Ferre S, Rubio A, Fuxe K. Stimulation of adenosinc A2 receptor induces catalepsy. Neurosci Lett 1991;130:162-5.
196. Caporali MG, Scotti de Carol is A, Popoli P. N-Ethyl-carboxamide inhibits perioral dyskinesias induced by sulpiride + SKF 38393 in rabbits. Eur J Pharmacol 1992;223:15-8.
197. Ferre S, Von Euler G, Johansson B, Fredholm BB, Fuxe K. Stimulation of high affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptor in rat striatal membranes. Proc Natl Acad Sci USA 1991;88:7238-41.
198. Kanda T, Shiozaki S, Shimada J, Suzuki F, Nakamura J. KFI7837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Eur J Pharmacol 1994;256:263-8.
199. Kweon YS, Kim KS. Effect of caffeine on haloperidol-induced catalepsy in the rat. J Cathol Med Coll 1992;45:327-30.
200. Blin O, Samuel D, Guieu R, Pouget J, Nieoullon A, Serratrice G. Report of case with both amyotrophic lateral sclerosis and Huntington chorea. Increase in CSF aspartate level. Rev Neurol 1992;148:144-6.
201. Cullen N, Carlen PL. Electrophysiological actions of acetate, a metabolite of ethanol on hippocampal dentate granule neurons: interactions with adenosine. Brain Res 1992;588:49-57.
202. Diamond I, Gordon AS. The role of adenosine in mediating cellular and molecular responses to ethanol. In: Jansson B, Jomvall H, Rydberg U, Terenius L, Vallee BL, eds. Toward a molecular basis of alcohol use and abuse. 1994:175-83.
203. Proctor WR, Dunwiddie TV. Behavioral sensitivity to purinergic drugs parallels ethanol sensitivity in selectively bred mice. Science 1984;224:519-21.
204. Proctor WR, Baker RC, Dunwiddie TV. Differential CNS sensitivity to PIA and theophylline in long sleep and short sleep in mice. Alcohol 1985;2:287-91.
205. Dar MS, Clark M. Tolerance to adenosine's accentuation of ethanol induced motor incoordination in ethanol tolerant mice. Alcohol Clin Exp Res 1992;16:1138-46.
206. Dar MS. Central adenosinergic system involvement in ethanol-induced motor coordination in mice. J Pharmacol Exp Ther 1990;255:1202-9.
207. Dar MS. Functional correlation between subclasses of brain adenosine receptor affinities and ethanol induced motor incoordination in mice. Pharmacol Biochem Behav 1990;37:747-53.
208. Linden J, Taylor HE, Feldman MD, Woodward EB, Ayers CR, Ripley ML, Iflah S, Patel A. The precise Radioimmunoasay of Adenosine; Minimization of Sample Collection Artifacts and Immunocrossreactivity. Annal Biochem 1992;201:246-254.